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Summary: Staphylococcus aureus infections are associated with considerable 
morbidity and, in certain situations, mortality. The association between the 
nasal carriage of S. au?eus and subsequent infection has been comprehensively 
established in a variety of clinical settings, in particular, patients undergoing 
haemodialysis and continuous ambulatory peritoneal dialysis (CAPD), and 
in patients undergoing surgery. Postoperative wound infections are associated 
with a high degree of morbidity and represent an important medical issue. 
Until recently, eradication of S. aureus nasal carriage by various topical and 
systemic agents had proved unsuccessful. Mupirocin is a novel topical 
antibiotic with excellent antibacterial activity against staphylococci. Recent 
studies have demonstrated that intranasal administration of mupirocin is 
effective in eradicating the nasal carriage of S. aurens and in reducing the 
incidence of S. aureus infections in haemodialysis and CAPD patients. It 
has been suggested that sufficient evidence now exists to test the hypothesis 
that eradication of the carrier state in surgical patients preoperatively may 
reduce the incidence of S. aureus postoperative wound infections. 
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Introduction 
Staphylococcus azuezu is one of the most important causes of nosocomial- 
and community-acquired infections. Although staphylococci are common 
inhabitants of the skin and the mucous membranes, the anterior nares 
provide the principal reservoir for these organisms. The general population, 
health care workers and patients can become intermittent or persistent 
nasal carriers of S. auyeus, although the prevalence of nasal carriage varies 
widely depending upon the population.’ Studies have shown that 1 O-l 5% of 
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healthy adults carry S. aUreUS in their nares; this figure rises to approximately 
20-35% in hospital personnel.* Many patient groups have higher rates of 
S. atireUS nasal carriage in comparison to the general population and health 
care workers, such as patients infected with HIV and those treated by 
haemodialysis and continuous ambulatory peritoneal dialysis (CAPD).3-6 
The postulated sequence of events which leads to infection is initiated 
with S. aureus nasal carriage. The organisms are then disseminated via 
hand carriage to other body sites where infection can occur when breaks 
in the dermal surfaces, by vascular catheterization or surgical incisions, 
have occurred. S. aUYeUS is the most common organism responsible for 
postoperative wound infections and a leading cause of septicaemia, in- 
travenous catheter-related infections and skin and soft-tissue infections. 
Auto-infection of surgical wounds by S. aUreUS is common, and is 
associated with considerable morbidity and represents an important medical 
and economic problem. To date, no comprehensive studies have been 
undertaken to demonstrate whether the eradication of the carrier state 
would reduce the rate of wound infections by S. aureus. However, recent 
studies in patients undergoing haemodialysis6 and CAPD7 have shown that 
eradication of nasal carriage of S. aUreUS significantly reduces the incidence 
of infection in these patients. The evidence, therefore, suggests that erad- 
ication of the carrier state in patients preoperatively may reduce the rate 
of postoperative wound infections with S. au~eus.~ Indeed, this idea has 
been supported by a study, with historical controls, recently carried out by 
Kluytmans et aZ.9 
Staphylococcus aweus nasal carriage and infection 
The significance of nasal carriage of staphylococci in the epidemiology of 
staphyloccocal infection has been recognized for 40 years.i Tulloch” re- 
ported that staphylococci isolated from skin lesions in patients with chronic 
staphylococcal skin infection were of the same phage-type as staphylococci 
isolated from the anterior nares of patients in 88% of instances in which 
staphylococci were typable. 
Infection in patients undergoing haemodialysis 
Infection in haemodialysis patients is associated with considerable morbidity 
and is the second leading cause of mortality in this group of patients. The 
most common site of infection is that related to the vascular access site, 
and studies have shown that S. atireUS accounts for 70-92% of these 
infections.‘i S. aUYeUS nasal carriage in haemodialysis patients is relatively 
high, with up to 70% of patients carrying S. aUreUS in their anterior nares.6 
A direct link between nasal carriage of S. aUreUS and subsequent infections 
by the same organism was demonstrated in a five year prospective study 
of haemodialysis patients.6 Yu et aZ.6 found that of 16 dialysis patients with 
S. ~UWUS infections, 14 were nasal carriers of staphylococci. Moreover, 93% 
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(13/14) of S. aUreUS infected carriers were found to be infected with the 
same phage-type as that carried in their nares. Importantly, patients who 
were nasal carriers of S. aUreUS had a significantly higher incidence of 
staphylococci infections than non-carriers. Similarly, in a study carried out 
by Ena et ~1.‘~ patients who developed staphylococcal infections while 
undergoing haemodialysis were found to be infected by strains persistently 
carried in their nares. 
Infection in patients undergoing CAPD 
Studies evaluating patients on long-term CAPD have demonstrated the 
association between nasal carriage of S. aureus and subsequent infection in 
CAPD patients.13 Peritonitis and exit-site infections are major complications 
of CAPD and are a leading cause of mortality in this group of patients. 
Sewell et 121.‘~ studied 30 patients, of which four were chronic S. aUreUS 
carriers, six intermittent carriers and 20 non-carriers. Of the chronic 
carriers, three patients developed five episodes of exit-site infections and 
six episodes of peritonitis, whereas three of the intermittent carriers de- 
veloped three episodes of exit-site infections and one episode of peritonitis. 
In contrast, only four of the 20 non-carriers developed four episodes of 
exit-site infections and one of peritonitis. Chronic carriers, therefore, appear 
to be at a higher risk of developing S. aureus-related infections. In a 
subsequent study by Kim et aZ.14 10 of 12 CAPD patients were found to 
have isolates of the same phage-type in cultures of the exit-site and peritoneal 
fluid. Furthermore, of the 12 patients, seven had isolates with the same 
phage-type in cultures from the nares, hands and peritoneal fluid. 
In a study in which the number of exit-site infections in 87 CAPD 
patients was recorded over eight months, patients who were nasal carriers 
were found to have a 6,7-fold increase in the incidence of exit-site infections 
compared with patients with negative cultures of the nares.5 In a similar 
study in which 43 patients, 16 chronic carriers and 12 intermittent carriers, 
underwent CAPD prospectively for 15 months, 16 episodes of peritonitis 
occurred in the carrier group compared with none in the non-carrier group. 
Moreover, of those patients evaluated, 100% of strains isolated from the 
nares and the peritoneum were found to be of identical plasmid pattern.” 
In a study carried out by Luzar et uZ.,~ the relationship between the nasal 
carriage of S. aUYeUS and subsequent catheter exit-site infection or peritonitis 
was assessed in 140 consecutive patients who were new to CAPD. Of these 
patients 63 were nasal carriers at the initiation of treatment. Luzar et aZ.l 
found a fourfold higher incidence of exit-site infections in nasal carriers in 
comparison with non-carriers. The probability of remaining free of an exit- 
site infection after 18 months on CAPD was 92% among non-carriers and 
54% in carriers (P=O.O12). Furthermore, among nasal carriers, 11 of 31 
episodes of peritonitis were caused by S. auyeus, compared with none of 
36 episodes in the non-carriers. 
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Methicillin-resistant 5’. UUY~US (MRSA) nasal carriage in patients un- 
dergoing CAPD is associated with an increased risk of CAPD-related 
infections in comparison with methicillin-susceptible S. UUY~US (MSSA) 
nasal carriers and non-carriers.16 In a recent study, patients who were 
MRSA carriers were found to have an increased rate of exit-site infections 
and peritonitis. The risk of being free from MRSA peritonitis after one 
year on CAPD in the carrier group was 65 vs. 96% in the non-carrier group 
(PcO.01). Similarly, the risk of being free from an exit-site infection after 
one year on CAPD was 67% in the carrier group in comparison with 96% 
in the non-carrier group (P<O*01).‘6 The number of patients who had a 
combination of CAPD-related infections or multiple episodes of peritonitis 
was also significantly higher in the carrier group than in the non-carrier 
group (P<O*OOl). Moreover, MRSA nasal carriers suffered an increased 
number of catheter losses and CAPD drop-outs in comparison to MSSA 
carriers and non-carriers.i6 
Infection in HIV-infected and AIDS patients 
Recent studies have demonstrated an increased prevalence of S. azueus 
carriage among HIV-infected patients3’17 and patients with AIDS.18 In a 
study by Weinke et ~1,~ the frequency of nasopharyngeal S. aureus carriage 
in HIV patients and its relationship to the incidence of S. azueus septicaemia 
was examined. The study, conducted over eight months, found that 44% 
(60/136) of HIV-infected patients were nasal carriers of S. uuyeus. In 
comparison only 31% (12/39) patients with chronic disease and 23% (1 l/ 
47) healthy hospital staff demonstrated S. aureus nasal carriage. Of eight 
HIV-infected patients with S. azueus septicaemia all were found to be nasal 
carriers. In contrast, no episodes of septicaemia occurred in non-colonized 
patients (P<O.Ol). 
Postoperative wound infections 
Postoperative wound infections affect at least 920 000 of the 23 million 
patients who undergo surgery each year in the USA.19 Surgical site infections 
are associated with high degree of morbidity and have important medical 
consequences in terms of prevention and treatment. S. aureus can account 
for up to 19% of postoperative wound infections in patients who are nasal 
carriers of S. uureus2’ (Table I). For several decades, it has been known 
that S. aureus nasal carriage by patients predisposes to postoperative wound 
auto-infection. Auto-infection of surgical wounds by S. aUTeUs was first 
documented in 1 95921,22 and the early 1 960s.20,23-27 In a study of 125 patients 
undergoing major surgery, patients with positive preoperative S. auveus 
nasal cultures demonstrated a postoperative wound infection rate of 37%. 
In comparison, those patients with negative preoperative nasal cultures 
demonstrated an 11% infection rate.21 Moreover, of those patients who were 
staphylococcal nasal carriers, S. aureus was the organism isolated from 94% 
of postoperative wound cultures. In contrast, a variety of organisms were 
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Table I. Incidence of postoperative wound infection in nasal carriers and non-takers of 
Staphylococcus aureus 
Incidence of wound infection 
First author 
Year of No. infected/ No. infected/ % 
report no. colonized no. not colonized Endogenous* 
White2’ 
Williams2* 
Public Health 
Laboratory’r McNei11z4 
Hendersor? 
BassettZ6 
Caliaz7 
1964 20/106 (19%) 28/345 (8%) 66 
1959 201276 (7%) 71342 (2%) 5.5 
1960 73/821 (9%) 158/2235 (7%) 1 12 74 (16 II/l13 (10%) 2 
1961 30 22/264 (8%) IS/569 (3%) 
1963 24/442 (5%) 6/78 (8%) 58 
1969 16/96 (17%) 16/173 (9%) 100 
* By phage-typing-showing same strains in preoperative nasal culture as identified in postoperative 
wound infection. 
isolated from postoperative wound cultures in non-carriers. Furthermore, 
92% of nasal carriers with postoperative staphylococcal wound infections 
demonstrated identical S. ~UWUS phage-types from both nose and wound 
cultures. 
Subsequent studies have shown the incidence of surgical wound sepsis 
in nasal carriers of S. aUreUS ranges from 5-19% (Table I). Moreover, 
30-100% of wounds were infected with phage-types that were in- 
distinguishable from those in the patient’s nose. In comparison, the post- 
operative infection rate in non-carriers was between 2-10% (Table I). 
Eradication of Staphylococcus aureus nasal carriage and the reduction 
in the incidence of infections 
The link between nasal carriage of S. uuwus and the aetiology of subsequent 
infections caused by this organism is well established in both haemodialysis/ 
CAPD patients and surgical patients. However, eradication of the carrier 
state in patients prior to surgery, and the concomitant reduction in post- 
operative wound infections with S. aureus, have yet to be fully evaluated.’ 
Mupirocin (pseudomonic acid) has been shown to have good in-vitro 
activity against clinical isolates of S. LZUY~US,~~ and the efficacy of mupirocin 
in eradicating nasal S. aUreUS carriage in haemodialysis patients and healthy 
control volunteers has been comprehensively evaluated in several stud- 
ies. 29-33 The use of mupirocin has also been advocated to eradicate MRSA 
nasal colonization in hospital staff and patients in the control of epidemic 
MRSA.34,3j Moreover, recent studies have demonstrated the efficacy of 
mupirocin, in reducing both the carriage and the incidence of S. aweus 
infection among patients undergoing haemodialysis and CAPD.7*36 
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Haemodialysis and CAPD patients 
Several studies carried out by Boelaert et a1.36,37 and Holton et aZ.38 have 
evaluated the efficacy of mupirocin in eradicating S. auyeus nasal carriage 
and reducing the incidence of S. aweus infections in haemodialysis patients. 
In a prospective, double-blind, placebo-controlled trial of 34 nasal carriers, 
intranasal application of 2% mupirocin ointment three times daily for 
two weeks followed by three times weekly applications for nine months, 
significantly reduced the incidence of S. aureus nasal carriage. Indeed, only 
6% of nasal cultures in the mupirocin arm of the study were positive for 
S. aureus in comparison with 58% in the placebo arm of the study. There 
was also a significant reduction in the incidence of S. aureus infections, 
with one episode in the mupirocin group in comparison with six in the 
placebo group.36 A subsequent study by Boelaert et aZ.39 demonstrated that 
continuous therapy with mupirocin was superior to intermittent therapy. 
The efficacy of mupirocin in reducing the incidence of S. aureus- 
associated bacteraemias was also evaluated by Boelaert et aZ.37 in patients 
undergoing haemodialysis. In a prospective study, Boelaert et aZ.37 applied 
2% calcium mupirocin to stable S. aweus nasal carriers in the haemodialysis 
unit, three times daily for five days then three times weekly for six months 
and thereafter once weekly for the subsequent 18 months of the study. 
This regimen eradicated nasal S. aweus carriage in 96.3% of surveillance 
cultures and reduced fourfold the incidence of S. aureus bacteraemia per 
patient year among all dialysis patients. S. aweus was responsible for four 
out of 23 episodes of bacteraemia (17.4%) following mupirocin treatment. 
In comparison, the incidence of S. aweus bacteraemia assessed from 
historical controls was reported to be 18 out of 33 bacteraemia episodes 
(54.5%). Eradication of S. aureus from the nares did not lead to overgrowth 
by other organisms and the authors concluded that nasal mupirocin was 
effective in eradicating nasal carriage of S. aweus and decreasing the 
incidence of bacteraemias caused by this pathogen. 
The findings of Boelaert et aZ.36,37 were supported in a study carried out 
by Holton et aZ.38 in which nasal mupirocin was applied to the anterior 
nares of patients undergoing haemodialysis. Holton et aZ.38 treated 22 
haemodialysis patients who were identified as S. aweus nasal carriers. The 
eradication rate immediately following the completion of therapy was 77% 
(17/22). Of the 17 patients who were culture-negative at completion of 
therapy, all remained free from S. aureus infections at three months follow- 
up. In contrast, two out of five patients (40%) who remained nasal culture- 
positive following mupirocin treatment suffered a S. azweus infection. Ten 
out of 46 patients (22’Y) o not enrolled in the study but followed concurrently 
had a significantly higher incidence of S. aweus infection (P=O.O3). 
In a recent study, the efficacy of mupirocin in the eradication of nasal 
S. aweus in CAPD patients and the reduction in the incidence of CAPD- 
related infections was evaluated.’ Ninety-four CAPD patients were enrolled 
in the study and of these 47.5% were S. aureus nasal carriers. A retrospective 
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assessment of 74 CAPD patients served as historical controls. Two percent 
mupirocin ointment, applied three times a day for seven days to the patients’ 
nares, eradicated nasal S. UUY~US carriage in 100% of patients. The incidence 
of S. aureus-related peritonitis and exit-site infections was also significantly 
reduced following mupirocin treatment. Only two episodes of peritonitis 
occurred in CAPD patients, in contrast to 18 episodes in historical controls. 
Exit-site infections accounted for eight and 19 episodes in CAPD patients 
and historical controls, respectively. 
Surgical patients 
The efficacy of mupirocin in the reduction of both S. aweus nasal carriage 
and subsequent infection in patients undergoing haemodialysis and CAPD 
has prompted Wenzel’ to suggest that sufficient evidence now exists to test 
the hypothesis that eradication of the carrier state would reduce the incidence 
of postoperative wound infections with S. QUY~US. Indeed, this has been 
reported recently in a historically controlled study conducted by Kluytmans 
et aZ.9 In this study, mupirocin nasal ointment was applied to the nose 
twice daily for five days, commencing one day prior to the operation, in 
629 patients undergoing cardiothoracic surgery during a 12 month period. 
The overall postoperative rate of infection assessed from 983 historical 
controls was 8.9%, and of these 3.5% were caused by S. aureus. In com- 
parison, the incidence of all postoperative wound infections, and in par- 
ticular those caused by S. aweus were significantly reduced during the 
period of mupirocin treatment, with figures of 1.8% (P<O.OOOl) and 0.6% 
(P<O.O005), respectively. S. aweus was isolated from four patients with 
postoperative wound infections following mupirocin treatment. However, 
the preoperative nasal cultures from these four patients did not grow S. 
aweus. Phage-typing showed that two of the isolates were identical to the 
type isolated previously from the nose of one of the nurses on the ward. 
Possibly, the infection was acquired postoperatively in the ward. Results, 
therefore, suggest that preoperative application of mupirocin reduces nasal 
carriage and reduces the incidence of postoperative wound infections by 
S. Lzure!us. However, it must be remembered that this conclusion is based 
on only one historically controlled study. Large randomized, placebo- 
controlled clinical trials are required to assess more fully the efficacy of 
applying mupirocin preoperatively to reduce the incidence of postoperative 
wound infections. One such clinical trial is underway at the College of 
Medicine, University of Iowa, USA. 
Resistance 
The topical use of any antibiotic is invariably associated with concerns 
about the emergence of resistance.39 Mupirocin-resistant S. aweus have 
rarely, however, been encountered in patients treated with mupirocin to 
prevent haemodialysis or peritoneal dialysis-associated infections. In a nine 
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month study by Boelaert et aZ.,36 mupirocin was applied to the anterior 
nares of stable S. aweus nasal carriers undergoing haemodialysis; three 
times a day for two weeks followed by three times a week for the remaining 
nine months. Throughout the study all S. aweus isolates remained mu- 
pirocin sensitive [minimum inhibitory concentration (MIC) I 1 mg/L]. In 
a subsequent study of haemodialysis patients with stable S. aweus nasal 
carriage, mupirocin was applied to the anterior nares three times a day for 
five days, then three times weekly for six months and thereafter once weekly 
for the subsequent 18 months of the study. Among the 29 S. azureus strains 
recovered from subsequent surveillance cultures of the nares, only one 
mupirocin-resistant strain was found (MI0512 ug/mL),37 i.e. one resistant 
isolate over 108 patient years. Further studies by Boelaert 
et aZ.40,41 on the application of mupirocin to haemodialysis patients who 
were S. aweus nasal carriers have not demonstrated the development of 
mupirocin resistance. 
Low- and high-level resistance by S. aweus to mupirocin has, however, 
been reported in the UK and is well documented in several letters to 
journals42-45 and in the general literature.46’47 Despite this, resistance among 
S. aUYeUS to mupirocin remains uncommon. A multi-centre UK survey 
found only 0.3% of 7137 S. aweus isolates to be resistant to mupirocin 
(MIC >4 mg/L) and only four of these 23 isolates (17%) were highly 
resistant (MIC >512 mg/L).44 In a separate study, during a MRSA outbreak 
in a Spanish hospital, an extensive screening programme combined with 
the use of intranasal mupirocin brought a two-year MRSA outbreak under 
control, 53 of 530 patients (10%) carried MRSA with low-level resistance 
to mupirocin (MICs 8-32 mg/L), of which 38 (72%) had previously had 
mupirocin-sensitive strains.48 
The overall incidence of S. aureus strains showing high-level resistance 
to mupirocin (MICs >512 mg/L) remains extremely low, despite increasing 
worldwide usage of mupirocin. Where high level resistance to mupirocin 
has been encountered, such strains have generally been associated with 
patients on dermatology wards42,43,45 or others receiving long-term mupirocin 
therapy of several weeks in duration.44 In this setting, it has been suggested 
that there may be an environmental reservoir contributing to the spread of 
mupirocin-resistant isolates.49 
Since the development of resistance to mupirocin is a cause for concern 
and the use of mupirocin preoperatively may encourage the emergence of 
mupirocin-resistant MRSA, alternative topical and systemic agents are avail- 
able which can be used to eradicate the nasal carriage of S. azweus with varying 
degrees of success. Since it is not the intention of this paper to review 
alternative agents, readers are referred to a review of the subject by Hudson.” 
Dosing regimen for intranasal mupirocin 
The duration and frequency of mupirocin dosing have varied between 
studies. Overall the clinical data support twice daily use of intranasal 
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mupirocin for five days. Minimal dose requirements, to reduce the emer- 
gence of mupirocin resistance, have been investigated by Casewell and 
Hills1 in 44 stable nasal carriers of MSSA. A single dose of mupirocin, or 
a regimen of four times daily for two days, eliminated nasal carriage of S. 
UUY~US within 24 h. Seven days after the single dose and the two day course, 
92 and 96% of subjects, respectively, remained free of nasal S. aUYeUS 
carriage. Recently, data from a one year prospective cohort study of S. 
~UWUS nasal carriers given treatment with mupirocin or placebo were 
reported.j2 All subjects received only five days of active drug or placebo. 
At six months, nasal carriage for S. aUYeUS was 48% in the treatment group 
vs. 72% in controls (P=O.O54). At one year, nasal carriage was 53 vs. 76%, 
respectively (P=O.O56). Thus, a single brief treatment course of topical 
nasal mupirocin reduced nasal carriage for up to one year. Therefore, it 
would seem appropriate to recommend the use of mupirocin for five days, 
particularly in cases of MRSA. 
Conclusion 
Staphylococcus aweus remains a leading cause of infection in several clinical 
areas. In particular, S. aUreUS is responsible for a large proportion of 
postoperative wound infections and infections in patients undergoing 
haemodialysis or peritoneal dialysis. The significance of nasal carriage of 
S. aweus in the epidemiology of infection has been comprehensively 
established. Indeed, nasal carriage of S. aUreUS predisposes patients to auto- 
infection. Postoperative wound infections are associated with considerable 
morbidity and place a substantial medical and economic burden on both 
the patient and hospital. Between 30 and 100% of postoperative wound 
sepsis can be the result of endogenous strains of S. uuveus. The reduction 
or prevention of postoperative wound infection by S. aweus is, therefore, 
an important medical goal. Elimination of nasal carriage of S. aUYeUS can 
be achieved by various systemic and topical antibodies: however, topical 
mupirocin has been shown to be particularly effective. The eradication of 
the nasal carriage of S. aweus in haemodialysis and CAPD patients is 
associated with a significant reduction in the incidence of infections. Ex- 
trapolation from these results would suggest that elimination of nasal 
carriage of S. aweus in patients undergoing surgical procedures might 
reduce the incidence of postoperative wound infections due to this organism. 
This hypothesis has been examined in a historically controlled clinical trial 
carried out by Kluytmans et ~1.~ in the Netherlands, and the results suggested 
a reduction in postoperative wound infections following eradication of 
S. aweus nasal carriage preoperatively. To corroborate these results, a large, 
randomized, placebo-controlled clinical trial is underway at the College of 
Medicine, University of Iowa, USA. 
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